Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT06095752 Recruiting - Multiple Myeloma Clinical Trials

Multiple Myeloma Prognostic Indices

Start date: November 1, 2023
Phase:
Study type: Observational

The aim of this study was to evaluate the impact of albumin / fibrinogen ratio, blood viscosity and RDW on the prognosis of a newly diagnosed MM patients

NCT ID: NCT06087653 Recruiting - Multiple Myeloma Clinical Trials

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Start date: October 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives - To assess the immunologic activity of natural killer (NK) cells and T cells for innate and humoral immunity. - To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations. - To determine pharmacodynamic (PD) changes with STAR-LLD in a panel of biomarkers associated with clinical response to lenalidomide. - Evaluate changes in efficacy indicators including objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Exploratory Objective - To assess the impact of STAR-LLD on patient reported symptoms and outcomes. Primary Endpoints - The grade, frequency, and relationship of treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESIs): (gastrointestinal [GI] toxicity, fatigue, hematologic toxicity, rash (non-infusion site). - The observation of dose-limiting toxicities (DLTs) of STAR-LLD during Cycle 1. Secondary Endpoints - Immune profiles, functional assays for NK cell activation and antigen specific T-cell activity. - Blood concentrations of lenalidomide at on Day 1 and at steady state. - Changes in biomarkers during treatment. - Rate of complete response, very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease. - Determination of ORR, PFS, and DOR

NCT ID: NCT06084962 Recruiting - Clinical trials for Relapse/Refractory Multiple Myeloma

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Start date: October 20, 2023
Phase: Phase 1
Study type: Interventional

Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

NCT ID: NCT06073353 Recruiting - Multiple Myeloma Clinical Trials

Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma

THRIVE-M
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This clinical trial aims to evaluate whether a psychosocial mobile application (THRIVE-M), is efficacious for improving quality of life, psychological distress, and fatigue in patients living with multiple myeloma compared to usual care.

NCT ID: NCT06068400 Recruiting - Clinical trials for Multiple Myeloma in Relapse

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

Start date: September 13, 2023
Phase: N/A
Study type: Interventional

This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for multiple myeloma.

NCT ID: NCT06066359 Recruiting - Myeloma Clinical Trials

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.

NCT ID: NCT06066346 Recruiting - Multiple Myeloma Clinical Trials

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Start date: September 27, 2023
Phase: Phase 2
Study type: Interventional

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

NCT ID: NCT06062537 Recruiting - Multiple Myeloma Clinical Trials

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

TEC-CARE
Start date: September 19, 2023
Phase:
Study type: Observational

200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria. This is a multicenter, prospective, observational study.

NCT ID: NCT06060080 Recruiting - Multiple Myeloma Clinical Trials

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Start date: April 22, 2022
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness and safety of PEG-rhG-CSF injection for the reconstruction of neutrophil cells after autologous hematopoietic stem cell transplantation in lymphoma/multiple myeloma patients.

NCT ID: NCT06057402 Recruiting - Multiple Myeloma Clinical Trials

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

MagnetisMM15
Start date: October 3, 2023
Phase: Phase 4
Study type: Interventional

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.